CXCR4-directed [68Ga]PentixaFor and [177Lu]/[90Y]PentixaTher, however, meet the urgent need to provide this innovative treatment strategy to patients affected with advanced blood cancer. This evidence concerns the gene CXCR4 and hematopoietic and lymphoid system neoplasm.